406 related articles for article (PubMed ID: 14556923)
21. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?
Geisler J
Br J Cancer; 2011 Mar; 104(7):1059-66. PubMed ID: 21364577
[TBL] [Abstract][Full Text] [Related]
22. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Rose C
Am J Clin Oncol; 2003 Aug; 26(4):S9-16. PubMed ID: 12902872
[TBL] [Abstract][Full Text] [Related]
23. Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer.
Lipsitz M; Delea TE; Guo A
Curr Med Res Opin; 2010 Oct; 26(10):2315-28. PubMed ID: 20731528
[TBL] [Abstract][Full Text] [Related]
24. Emerging role of aromatase inhibitors in the treatment of breast cancer.
Harvey HA
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):32-5. PubMed ID: 9556789
[TBL] [Abstract][Full Text] [Related]
25. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
Geisler J; King N; Dowsett M; Ottestad L; Lundgren S; Walton P; Kormeset PO; Lønning PE
Br J Cancer; 1996 Oct; 74(8):1286-91. PubMed ID: 8883419
[TBL] [Abstract][Full Text] [Related]
26. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
27. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
Mouridsen H; Gershanovich M; Sun Y; Pérez-Carrión R; Boni C; Monnier A; Apffelstaedt J; Smith R; Sleeboom HP; Jänicke F; Pluzanska A; Dank M; Becquart D; Bapsy PP; Salminen E; Snyder R; Lassus M; Verbeek JA; Staffler B; Chaudri-Ross HA; Dugan M
J Clin Oncol; 2001 May; 19(10):2596-606. PubMed ID: 11352951
[TBL] [Abstract][Full Text] [Related]
28. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Buzdar A; Jonat W; Howell A; Jones SE; Blomqvist C; Vogel CL; Eiermann W; Wolter JM; Azab M; Webster A; Plourde PV
J Clin Oncol; 1996 Jul; 14(7):2000-11. PubMed ID: 8683230
[TBL] [Abstract][Full Text] [Related]
29. Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
Dixon JM; Love CD; Renshaw L; Bellamy C; Cameron DA; Miller WR; Leonard RC
Endocr Relat Cancer; 1999 Jun; 6(2):227-30. PubMed ID: 10731113
[TBL] [Abstract][Full Text] [Related]
30. Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate.
Dranitsaris G; Leung P; Mather J; Oza A
Anticancer Drugs; 2000 Aug; 11(7):591-601. PubMed ID: 11036964
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
Dixon JM; Jackson J; Renshaw L; Miller WR
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):295-9. PubMed ID: 14623524
[TBL] [Abstract][Full Text] [Related]
32. Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer.
Tominaga T; Adachi I; Sasaki Y; Tabei T; Ikeda T; Takatsuka Y; Toi M; Suwa T; Ohashi Y
Ann Oncol; 2003 Jan; 14(1):62-70. PubMed ID: 12488294
[TBL] [Abstract][Full Text] [Related]
33. Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting?
Buzdar AU
Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):6-10. PubMed ID: 11900212
[TBL] [Abstract][Full Text] [Related]
34. An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole.
Tobias JS; Howell A
Eur J Cancer; 2004 Aug; 40(12):1913. PubMed ID: 15288295
[No Abstract] [Full Text] [Related]
35. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
36. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Howell A; Robertson JF; Quaresma Albano J; Aschermannova A; Mauriac L; Kleeberg UR; Vergote I; Erikstein B; Webster A; Morris C
J Clin Oncol; 2002 Aug; 20(16):3396-403. PubMed ID: 12177099
[TBL] [Abstract][Full Text] [Related]
37. Examining quality of life issues in relation to endocrine therapy for breast cancer.
Thomas R
Am J Clin Oncol; 2003 Aug; 26(4):S40-4. PubMed ID: 12902876
[TBL] [Abstract][Full Text] [Related]
38. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Miller WR; Stuart M; Sahmoud T; Dixon JM
Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
[TBL] [Abstract][Full Text] [Related]
39. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
Mouridsen H; Chaudri-Ross HA
Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
